To sum up, serum levels of IL-17 and IL-23 decreased after both NB-UVB and MTX therapy confirming the importance of this axis in the pathogenesis of psoriasis and providing evidence, in particular, for a novel therapeutic mechanism of MTX in the disease. The gene discussed is IL17A; the disease is psoriasis.